New Weight-Loss drug candidate enters early human testing
NCT ID NCT07294235
First seen Dec 29, 2025 · Last updated May 07, 2026 · Updated 19 times
Summary
This early-stage study is testing an investigational drug called BGM1812 in healthy and non-diabetic overweight or obese Chinese adults. The main goal is to check the drug's safety and how the body processes it. Participants will receive either the drug or a placebo by injection, and researchers will monitor side effects and measure drug levels in the blood. This study does not aim to cure obesity but to gather safety data for future development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Yunnan University of Chinese Medicine
RECRUITINGKunming, Yunnan, 650000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.